CREO MEDICAL GROUP PLC (CREO) — Full Year Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the CREO MEDICAL GROUP PLC investor presentation. Throughout this recorded meeting, which is scheduled for forty five minutes, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the Q and A tab situated in the right corner of your screen. Simply type in your questions and press send. The company may not be your position to answer every question it receives in the meeting itself. However, the company can view all questions submitted today and publish written responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Craig Culliford, CEO. Good afternoon to you, sir. Good afternoon, everybody. Welcome to the call. So just jumping straight in. Financial highlights. So core revenue is up two and a half times over the previous year, which is a strong result on track for the guidance that we had in the market. Total group revenue just under 31,000,000. Again, broadly on track with analyst guy guidance. First revenues of our SPEEDICAL UltraSlim device, which is, you know, the device at the long road of a development process of miniaturizing the device to the point where it can be used in every single endoscope that might be used in the GI tract from the esophagus to the to the rectum, basically. Underlying operating loss is reduced, which is the first year we're seeing reducing losses, which was as expected, and gross margins are up. So all the indications that we we needed to see, we are seeing the first release of UltraSlim was a little bit later in the year than we expected. We had a few challenges in q two, but we still hit the number. But more importantly, the underlying administrative costs as well have come down sligh...